Nephros (NEPH) Competitors $1.50 +0.01 (+0.74%) As of 02/21/2025 04:00 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends NEPH vs. APT, TMDIF, CTSO, APYX, INO, MODD, NXL, MBOT, BLAC, and OMShould you be buying Nephros stock or one of its competitors? The main competitors of Nephros include Alpha Pro Tech (APT), Titan Medical (TMDIF), Cytosorbents (CTSO), Apyx Medical (APYX), Inovio Pharmaceuticals (INO), Modular Medical (MODD), Nexalin Technology (NXL), Microbot Medical (MBOT), Bellevue Life Sciences Acquisition (BLAC), and Outset Medical (OM). These companies are all part of the "medical equipment" industry. Nephros vs. Alpha Pro Tech Titan Medical Cytosorbents Apyx Medical Inovio Pharmaceuticals Modular Medical Nexalin Technology Microbot Medical Bellevue Life Sciences Acquisition Outset Medical Nephros (NASDAQ:NEPH) and Alpha Pro Tech (NYSE:APT) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their analyst recommendations, risk, media sentiment, profitability, community ranking, dividends, valuation, institutional ownership and earnings. Do analysts rate NEPH or APT? Nephros presently has a consensus target price of $5.00, indicating a potential upside of 218.67%. Given Nephros' stronger consensus rating and higher probable upside, equities analysts plainly believe Nephros is more favorable than Alpha Pro Tech.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Nephros 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00Alpha Pro Tech 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Which has higher valuation and earnings, NEPH or APT? Alpha Pro Tech has higher revenue and earnings than Nephros. Nephros is trading at a lower price-to-earnings ratio than Alpha Pro Tech, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioNephros$14.24M1.16-$1.58M-$0.09-17.43Alpha Pro Tech$61.23M1.01$4.19M$0.3715.19 Which has more volatility & risk, NEPH or APT? Nephros has a beta of 1.19, meaning that its share price is 19% more volatile than the S&P 500. Comparatively, Alpha Pro Tech has a beta of -0.64, meaning that its share price is 164% less volatile than the S&P 500. Does the media refer more to NEPH or APT? In the previous week, Nephros and Nephros both had 1 articles in the media. Nephros' average media sentiment score of 0.00 equaled Alpha Pro Tech'saverage media sentiment score. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Nephros 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Alpha Pro Tech 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Do institutionals and insiders believe in NEPH or APT? 41.1% of Nephros shares are held by institutional investors. Comparatively, 22.7% of Alpha Pro Tech shares are held by institutional investors. 4.1% of Nephros shares are held by insiders. Comparatively, 14.0% of Alpha Pro Tech shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term. Does the MarketBeat Community favor NEPH or APT? Alpha Pro Tech received 10 more outperform votes than Nephros when rated by MarketBeat users. Likewise, 100.00% of users gave Alpha Pro Tech an outperform vote while only 43.33% of users gave Nephros an outperform vote. CompanyUnderperformOutperformNephrosOutperform Votes1343.33% Underperform Votes1756.67% Alpha Pro TechOutperform Votes23100.00% Underperform VotesNo Votes Is NEPH or APT more profitable? Alpha Pro Tech has a net margin of 6.99% compared to Nephros' net margin of -6.86%. Alpha Pro Tech's return on equity of 6.70% beat Nephros' return on equity.Company Net Margins Return on Equity Return on Assets Nephros-6.86% -11.39% -8.30% Alpha Pro Tech 6.99%6.70%5.76% SummaryAlpha Pro Tech beats Nephros on 10 of the 16 factors compared between the two stocks. Get Nephros News Delivered to You Automatically Sign up to receive the latest news and ratings for NEPH and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart NEPH vs. The Competition Export to ExcelMetricNephrosSurgical & medical instruments IndustryMedical SectorNASDAQ ExchangeMarket Cap$15.71M$4.74B$5.84B$9.15BDividend YieldN/A39.90%4.75%3.85%P/E Ratio-17.4328.5326.1519.13Price / Sales1.1653.64435.3370.72Price / CashN/A51.1038.0134.83Price / Book1.966.577.644.62Net Income-$1.58M$90.91M$3.19B$245.94M7 Day Performance3.22%-2.39%-2.11%-2.62%1 Month Performance-1.94%-2.29%-0.49%-2.15%1 Year Performance-55.68%15.21%16.44%12.95% Nephros Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)NEPHNephros2.1432 of 5 stars$1.57+5.3%$5.00+218.7%-55.2%$15.71M$14.24M-17.4330News CoverageGap UpAPTAlpha Pro TechN/A$5.40-1.5%N/A+4.9%$59.40M$61.23M14.59120TMDIFTitan MedicalN/A$0.50flatN/A+646.3%$56.78M$17.63M-0.4050CTSOCytosorbents2.5387 of 5 stars$0.99-2.9%$4.67+371.3%+15.0%$54.14M$36.35M-2.75220Analyst ForecastAPYXApyx Medical1.4607 of 5 stars$1.43+1.4%N/A-25.2%$53.83M$52.35M-1.72270INOInovio Pharmaceuticals3.2227 of 5 stars$1.92-2.0%$12.40+545.8%-71.6%$50.11M$830,000.00-0.91320News CoverageMODDModular Medical2.8685 of 5 stars$1.20-0.8%$5.00+316.7%-38.4%$48.80MN/A-1.9020Gap UpNXLNexalin Technology1.2018 of 5 stars$3.52-5.4%$3.00-14.8%+794.1%$46.82M$110,000.00-5.503MBOTMicrobot Medical1.782 of 5 stars$2.31-9.4%$9.00+289.6%+25.4%$46.75MN/A-2.8920High Trading VolumeBLACBellevue Life Sciences AcquisitionN/A$10.93-2.6%N/A-67.4%$44.15MN/A0.00N/AGap UpOMOutset Medical1.6954 of 5 stars$0.79-3.1%$4.50+473.2%-72.7%$42.15M$130.38M-0.28520Earnings ReportNews Coverage Related Companies and Tools Related Companies Alpha Pro Tech Competitors Titan Medical Competitors Cytosorbents Competitors Apyx Medical Competitors Inovio Pharmaceuticals Competitors Modular Medical Competitors Nexalin Technology Competitors Microbot Medical Competitors Bellevue Life Sciences Acquisition Competitors Outset Medical Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:NEPH) was last updated on 2/22/2025 by MarketBeat.com Staff From Our PartnersCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredElon’s “New Gold”MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest brea...True Market Insiders | SponsoredMarket down? Do this now.During Trump's first term, his tariffs sent gold prices soaring. Investors who acted early made a fortune. Now...Colonial Metals | SponsoredThis Crypto Is Set to Explode in FebruaryIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this su...Crypto 101 Media | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredBuy this AI Stock Before Elon’s AnnouncementWith Trump back in office, xAI is primed to become the leader in generative AI, leaving competitors in the dus...InvestorPlace | SponsoredSecret financial plot unfolding in Washington DC… [DEVELOPING]What stocks are next up to soar in 2025? I believe I’ve found the answer - and it might surprise you. Yo...Timothy Sykes | SponsoredBuy NVDA Now? After weeks of volatility, did President Trump just turn Nvidia (NVDA) into a raging BUY? The beloved chip...Chaikin Analytics | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Nephros, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Nephros With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
